Topical Nepafenac as an Alternate Treatment for Cystoid Macular Edema in Steroid Responsive Patients

Warren, Keith A.; Fox, Jenni E.

doi:10.1097/iae.0b013e31817e7ead

Cited by 36 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2015; Rodrigues et al. 2016) and treatment for diabetic macular oedema (Callanan & Williams 2008), cystoid macular oedema (Warren & Fox 2008), pain after photorefractive keratectomy (Caldwell & Reilly 2008; Faktorovich & Melwani 2014; ), recalcitrant macular degeneration (Chen et al. 2010; Libondi & Jonas 2010), macular oedema after epiretinal surgery (Schoenberger et al.…”

Section: Discussionmentioning

confidence: 99%

Ophthalmic nepafenac use in the Netherlands and Denmark

Margulis¹,

Houben

Hallas

et al. 2017

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo describe nepafenac use in the Netherlands and Denmark with reference to its approved indications. For context, we also describe the use of ketorolac and diclofenac.MethodsWe identified users in the PHARMO Database Network (the Netherlands, 2008–2013) and the Danish national health registers (Denmark, 1994–2014). We described prevalence of cataract surgery and duration of use in patients with cataract surgery with and without diabetes.ResultsIn the Netherlands, 9530 nepafenac users (mean age, 71 years; 60% women) contributed 12 691 therapy episodes, of which 21% had a recently recorded cataract surgery. Of 2266 episodes in adult non‐diabetic patients with cataract surgery, 60% had one bottle dispensed (treatment duration ≤21 days). Of 441 episodes in adult diabetic patients with cataract surgery, 90% had up to two bottles dispensed (≤60 days).Denmark had 60 403 nepafenac users (mean age, 72 years; 58% women) and 73 648 episodes (41% had recorded cataract surgery). Of 26 649 nepafenac episodes in adult non‐diabetic patients with cataract surgery, 92% had one bottle dispensed. Of 3801 episodes in adult diabetic patients with cataract surgery, 99.8% had up to two bottles dispensed.Use patterns of nepafenac, ketorolac and diclofenac were roughly similar in the Netherlands, but not in Denmark.ConclusionLess than half of therapy episodes were related to cataract surgery; around 90% of episodes with surgery were within the approved duration. Underrecording of ophthalmic conditions and procedures was a challenge in this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Ophthalmic nepafenac use in the Netherlands and Denmark

Margulis¹,

Houben

Hallas

et al. 2017

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Therefore a prospective, open-label study was conducted to determine whether nepafenac might be of use as an alternative to topical steroids in this patient population. 42 Patients in this study had CME of at least 2 months duration either after cataract surgery or due to vitreoretinal interface disorders, and subgroup analysis showed significant improvement in visual acuity and in retinal thickness in the patients with pseudophakic CME. Other investigators have evaluated whether 1 NSAID might be more effective in the treatment of pseudophakic CME than another.…”

Section: Nsaidsmentioning

confidence: 93%

Pseudophakic Cystoid Macular Edema

Benitah¹,

Arroyo²

2010

International Ophthalmology Clinics

View full text Add to dashboard Cite

“…Both categories can be provided as eye drops immediately after the CME is diagnosed (clinically and/or angiographically) or after a short period of attendance due to the selflimiting character of the condition. The effectiveness of topically administered NSAIDs is proved by several studies (Miyake et al, 1980;Yannuzzi et l., 1981;Flach et al, 1991;Italian Diclofenac Study Group, 1997) and their use is suggested as alternative to steroids when possible (Warren & Fox, 2008) due to the well-known side effects after long-term administration of steroids (eg. elevation of IOP).…”

Section: Treatmentmentioning

confidence: 99%